NEW YORK, Jan. 27, 2017 /PRNewswire/ -- The federal multidistrict litigation established in the U.S. District Court, Eastern District of Louisiana for Taxotere permanent alopecia lawsuits continues to move forward, having issued Pretrial Order #12 on January 19th. Among other things, the Order stipulates that Service of Process be made on all non-Sanofi defendants by Wednesday, February 15, 2017. Liaison Counsel have also been directed to submit proposed deadlines for submission of a Master Complaint, Short Form Complaint, Master Answer, and Motions to Dismiss during today's scheduled meeting with the Court. (In Re: Taxotere (Docetaxal) Products Liability Litigation - MDL No. 2740)
"Our Firm is working with a number of Taxotere patients who allegedly experienced permanent hair loss due to the side effects associated with this chemotherapy medication. We are pleased that the federal litigation is progressing, and look forward to further developments in the near future," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free legal evaluations to breast cancer patients and others whose hair failed to grow back following chemotherapy with Taxotere.
Taxotere Hair Loss Allegations
The U.S. Food & Drug Administration first approved Taxotere to treat breast cancer in 1996. The agency has since cleared the chemotherapy agent to treat neck cancer, gastric cancer, prostate cancer and non-small cell lung cancer. Nearly two decades after its initial approval, the FDA announced that the Adverse Events section of the Taxotere label would be modified to note that cases of permanent alopecia had been reported among patients treated with the drug.
More than 700 Taxotere lawsuits are now pending in the centralized litigation underway in Louisiana. Plaintiffs involved in this proceeding claim that they were wrongly led to believe that the alopecia resulting from their cancer treatments would be temporary. Their complaints further allege that Taxotere hair loss is actually more likely to be permanent compared to alternative, equally affective chemotherapy drugs. Plaintiffs also point out that Sanofi-Aventis advised physicians, patients, and regulatory agencies in other countries, including the European Union and Canada, that Taxotere could result in permanent and disfiguring hair loss. Yet the Taxotere warnings included on the U.S. labeling were vague and misleading, as they merely cautioned that "hair generally grows back" following exposure to the drug.
Cancer patients who allegedly suffered permanent hair loss following Taxotere chemotherapy may be eligible to file a lawsuit of their own. To learn more about the available legal options, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP